{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T19:28:38Z","timestamp":1757705318921,"version":"3.35.0"},"reference-count":93,"publisher":"Wiley","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2556,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1111\/j.1529-8019.2008.00226.x","type":"journal-article","created":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T18:07:26Z","timestamp":1222884446000},"page":"S1-S14","source":"Crossref","is-referenced-by-count":9,"special_numbering":"supplement","title":["Etanercept provides a more physiological approach in the treatment of psoriasis"],"prefix":"10.1155","volume":"21","author":[{"given":"Gianfranco","family":"Altomare","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enzo","family":"Berardesca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Chimenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Giannetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torello","family":"Lotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Martini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Peserico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio Puglisi","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gino A.","family":"Vena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB1","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMra041320","article-title":"Psoriasis","volume":"352","author":"Schon","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB2","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0733-8635(05)70376-4","article-title":"Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment","volume":"14","author":"Koo","year":"1996","journal-title":"Dermatol Clin"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB3","first-page":"2577","article-title":"Inflammatory joint manifestations are prevalent in psoriasis: prevalence study of joint and axial involvement in psoriatic patients, and evaluation of a psoriatic and arthritic questionnaire","volume":"29","author":"Alenius","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB4","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/00015550252948130","article-title":"Quality of life and prevalence of arthritis reported by 5795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study","volume":"82","author":"Zachariae","year":"2002","journal-title":"Acta Derm Venereol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB5","first-page":"279","article-title":"Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis","volume":"15","author":"Gisondi","year":"2005","journal-title":"Eur J Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB6","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1172\/JCI200316069","article-title":"Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis","volume":"111","author":"Ritchlin","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1136\/ard.2007.075101","article-title":"Lower limbs enthesopathy in psoriatic patients without clinical signs of arthropathy: a hospital based case-control study","volume":"67","author":"Gisondi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","article-title":"Psoriasis causes as much disability as other major medical diseases","volume":"41","author":"Rapp","year":"1999","journal-title":"J Am Acad Dermatol"},{"issue":"2 Suppl","key":"10.1111\/j.1529-8019.2008.00226.x-BIB9","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S0190-9622(03)01136-8","article-title":"Quality of life issues in psoriasis","volume":"49","author":"Choi","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB10","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nature05663","article-title":"Pathogenesis and therapy of psoriasis","volume":"445","author":"Lowes","year":"2007","journal-title":"Nature"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB11","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/j.1365-2133.2007.08135.x","article-title":"Psoriasis: evolution of pathogenic concepts and new therapies through phases of translational research","volume":"157","author":"Guttman-Yassky","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB12","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.1600-0625.2007.00629.x","article-title":"Immunopathogenesis of psoriasis","volume":"16","author":"Sabat","year":"2007","journal-title":"Exp Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB13","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/eji.200535243","article-title":"CD56 bright CD16(-) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation","volume":"36","author":"Ottaviani","year":"2006","journal-title":"Eur J Immunol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB14","doi-asserted-by":"crossref","first-page":"494","DOI":"10.4049\/jimmunol.162.1.494","article-title":"IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes. Synergistic or antagonist effects with interferon-gamma; and tumor necrosis factor-alpha","volume":"162","author":"Albanesi","year":"1999","journal-title":"J Immunol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB15","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/eji.200535503","article-title":"IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis","volume":"36","author":"Wolk","year":"2006","journal-title":"Eur J Immunol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB16","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1084\/jem.20060244","article-title":"IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis","volume":"203","author":"Chan","year":"2006","journal-title":"J Exp Med"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB17","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nature05505","article-title":"Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis","volume":"445","author":"Zheng","year":"2007","journal-title":"Nature"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB18","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1365-3083.1988.tb01507.x","article-title":"An altered response by psoriatic keratinocytes to gamma interferon","volume":"28","author":"Baker","year":"1988","journal-title":"Scand J Immunol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB19","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nature06116","article-title":"Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide","volume":"449","author":"Lande","year":"2007","journal-title":"Nature"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB20","first-page":"115","article-title":"Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis","volume":"11","author":"Mussi","year":"1997","journal-title":"J Biol Regul Homeost Agents"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB21","doi-asserted-by":"crossref","first-page":"32633","DOI":"10.1074\/jbc.M400642200","article-title":"Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling","volume":"279","author":"Banno","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB22","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/j.1365-2133.2005.06440.x","article-title":"Overexpression of tumour necrosis factor-alpha-converting enzyme in psoriasis","volume":"152","author":"Kawaguchi","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB23","first-page":"264","article-title":"TNF-alpha and apoptosis: implications for the pathogenesis and treatment of psoriasis","volume":"1","author":"Victor","year":"2002","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB24","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/sj.jidsymp.5650037","article-title":"Mechanisms of action of etanercept in psoriasis","volume":"12","author":"Tan","year":"2007","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB25","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/ard.2003.018085","article-title":"Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis","volume":"63","author":"Goedkoop","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB26","doi-asserted-by":"crossref","first-page":"R326","DOI":"10.1186\/ar1182","article-title":"Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study","volume":"6","author":"Goedkoop","year":"2004","journal-title":"Arthritis Res Ther"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB27","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2133.2007.07945.x","article-title":"Anti-TNF-alpha chimeric antibody (Infliximab) inhibits activation of psoriatic CD4+ and CD8+ T lymphocytes and impairs dendritic cell functions","volume":"157","author":"Bedini","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB28","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.4049\/jimmunol.175.4.2721","article-title":"TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques","volume":"175","author":"Gottlieb","year":"2005","journal-title":"J Immunol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2310\/7750.2007.00006","article-title":"Efalizumab for the treatment of psoriatic arthritis","volume":"11","author":"Papp","year":"2007","journal-title":"J Cutan Med Surg"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB30","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-2133.2006.07344.x","article-title":"Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial","volume":"155","author":"Dubertret","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB31","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.semarthrit.2006.02.001","article-title":"Tumor Necrosis Factor antagonists: different kinetics and\/or mechanisms of action may explain differences in the risk for developing granulomatous infection","volume":"36","author":"Furst","year":"2006","journal-title":"Semin Arthritis Rheum"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB33","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/sj.jidsymp.5650034","article-title":"Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs","volume":"12","author":"Kohno","year":"2007","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.jidsymp.5650032","article-title":"Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes","volume":"12","author":"Haider","year":"2007","journal-title":"J Invest Dermatol Symp Proc"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB35","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1084\/jem.20071094","article-title":"Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses","volume":"204","author":"Zaba","year":"2007","journal-title":"J Exp Med"},{"issue":"Suppl. 3","key":"10.1111\/j.1529-8019.2008.00226.x-BIB36","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1086\/429998","article-title":"Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?","volume":"41","author":"Ehlers","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB37","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/sj.jidsymp.5650031","article-title":"Reactivation of latent tuberculosis by TNF blockade: the role of interferon-gamma","volume":"12","author":"Wallis","year":"2007","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB38","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jaad.2006.05.004","article-title":"Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients","volume":"55","author":"Malaviya","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB39","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1586\/17469872.2.3.335","article-title":"Anti-tumor necrosis factor therapies for psoriasis","volume":"2","author":"Vena","year":"2007","journal-title":"Expert Rev Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB40","doi-asserted-by":"crossref","first-page":"2","DOI":"10.5070\/D30W66C5GG","article-title":"A systematic review of adverse effects associated with topical treatments for psoriasis","volume":"9","author":"Bruner","year":"2003","journal-title":"Dermatol Online J"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB41","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/archderm.134.5.595","article-title":"Consensus workshop on the toxic effects of long-term PUVA therapy","volume":"134","author":"Morison","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB42","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jaad.2003.09.028","article-title":"Cost analysis of narrowband UVB phototherapy in psoriasis","volume":"50","author":"Langan","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB43","doi-asserted-by":"crossref","first-page":"318","DOI":"10.18553\/jmcp.2004.10.4.318","article-title":"Advancements in the treatment of psoriasis: role of biologic agents","volume":"10","author":"Rich","year":"2004","journal-title":"J Manag Care Pharm"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB44","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1046\/j.1523-1747.2003.12350.x","article-title":"The increased risk of skin cancer is persistent after discontination of psoralen-ultraviolet A: a cohort study","volume":"121","author":"Nijsten","year":"2003","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB45","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00403-006-0660-6","article-title":"The long-term efficacy and safety of new biological therapies for psoriasis","volume":"298","author":"Papp","year":"2006","journal-title":"Arch Dermatol Res"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB46","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2165\/00002018-200629010-00004","article-title":"Fulfilling an unmet need in psoriasis: do biologicals hold the key to improved tolerability?","volume":"29","author":"Shear","year":"2006","journal-title":"Drug Saf"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB47","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2165\/00002018-200629080-00004","article-title":"Safety of etanercept in psoriasis: a critical review","volume":"29","author":"Sanchez Carazo","year":"2006","journal-title":"Drug Saf"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB48","first-page":"1442","article-title":"Conventional systemic agents for psoriasis. A systematic review","volume":"33","author":"Strober","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB49","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1517\/14656566.8.5.617","article-title":"An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic options","volume":"8","author":"Leon","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB50","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/09546630500504754","article-title":"The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies","volume":"17","author":"Pearce","year":"2006","journal-title":"J Dermatolog Treat"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB51","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archderm.140.6.685","article-title":"Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine","volume":"140","author":"Opmeer","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB52","doi-asserted-by":"crossref","unstructured":"52. Saurat JH , Stingl G , Dubertret L , et\u00a0al.; for the CHAMPION Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2007 Nov 28.","DOI":"10.1111\/j.1365-2133.2007.08315.x"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB53","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1046\/j.1468-3083.2000.00058.x","article-title":"Methotrexate in psoriasis: 26 years\u2019 experience with low-dose long-term treatment","volume":"14","author":"Haustein","year":"2000","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB54","unstructured":"54. Zachariae C , M\u00f8rk NJ , Reunala T , et\u00a0al. The combination of etanercept and methotrexate increases the efficacy in active plaque psoriasis in patients with an inadequate response to methotrexate therapy: a pilot study. 21st World Congress Dermatology, Buenos Aires, 2007; Abstract ID 435."},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB55","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1468-3083.2006.01527.x","article-title":"Consistent control of psoriasis by continuous long-term therapy: the promise of biological treatments","volume":"20","author":"van de Kerkhof","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl. 2","key":"10.1111\/j.1529-8019.2008.00226.x-BIB56","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.jaad.2005.11.1088","article-title":"Efficacy of etanercept in an integrated multistudy database of patients with psoriasis","volume":"54","author":"Gordon","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB57","first-page":"1","article-title":"Etanercept and efalizumab for the treatment of psoriasis: a systematic review","volume":"10","author":"Woolacott","year":"2006","journal-title":"Health Technol Assess"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB58","unstructured":"58. van de Kerkhof P , Paolozzi L , Wajdula J. Etanercept 50\u00a0mg once weekly is effective and well tolerated in patients with moderate-to-severe plaque psoriasis. 66th Annual Meeting of the American Academy of Dermatology, San Antonio, 2008; Abstract ID 9477."},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB59","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/S0149-2918(03)80313-2","article-title":"An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis","volume":"25","author":"Weinberg","year":"2003","journal-title":"Clin Ther"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB60","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/09546630500472838","article-title":"Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy","volume":"17","author":"Gordon","year":"2006","journal-title":"J Dermatol Treat"},{"issue":"Suppl. 1","key":"10.1111\/j.1529-8019.2008.00226.x-BIB61","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1016\/j.jaad.2005.10.029","article-title":"Relapse, rebound, and psoriasis adverse events: an advisory group report","volume":"54","author":"Carey","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB62","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Vermeire","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB63","first-page":"31","article-title":"Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response","volume":"33","author":"Haraoui","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB64","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1136\/ard.2007.072397","article-title":"Decreased clinical response to infliximab in ankylosing spondylitis (AS) is correlated with anti-infliximab formation","volume":"66","author":"de Vries","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB65","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/ard.2006.065615","article-title":"Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis","volume":"66","author":"Bartelds","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB66","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archderm.143.6.719","article-title":"Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis","volume":"143","author":"Tyring","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB67","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/205873920601900123","article-title":"Once-weekly administration of high-dosage Etanercept in patients with plaque psoriasis: results of a pilot experience (POWER study)","volume":"19","author":"Cassano","year":"2006","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB68","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa066886","article-title":"Group. Etanercept treatment for children and adolescents with plaque psoriasis","volume":"358","author":"Paller","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB69","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2133.2005.06982.x","article-title":"Etanercept for the treatment of severe childhood psoriasis","volume":"154","author":"Papoutsaki","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB70","first-page":"25","article-title":"Psoriatic arthritis update","volume":"64","author":"Mease","year":"2006","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB71","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.09.002","article-title":"A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis","volume":"56","author":"Moore","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB72","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/j.1365-2133.2005.06948.x","article-title":"Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial","volume":"153","author":"Krueger","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB73","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0140-6736(05)67763-X","article-title":"Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial","volume":"367","author":"Tyring","year":"2006","journal-title":"Lancet"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB74","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/j.1365-2133.2007.08205.x","article-title":"Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks","volume":"157","author":"Krishnan","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB75","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. Systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB76","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.20009","article-title":"Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB77","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB78","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report","volume":"48","author":"Gomez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"Suppl. II","key":"10.1111\/j.1529-8019.2008.00226.x-BIB79","doi-asserted-by":"crossref","first-page":"ii37","DOI":"10.1136\/ard.62.suppl_2.ii37","article-title":"Role of tumor necrosis factor (TNF) host defence against tuberculosis: implications for immunotherapies targeting TNF","volume":"62","author":"Ehlers","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB80","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1086\/517519","article-title":"Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis","volume":"195","author":"Plessner","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB81","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2515\/therapie:2003074","article-title":"Retrospective analysis of adverse effects of infliximab in a hospital rheumatology service","volume":"58","author":"Cabou","year":"2003","journal-title":"Therapie"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB82","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","article-title":"Rates of serious infections, including site-specific and bacterial intracellular infections, in rheumatoid arthritis patients receiving anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"54","author":"Dixon","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB83","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/art.21568","article-title":"Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: association with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy","volume":"54","author":"Wolfe","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"Suppl","key":"10.1111\/j.1529-8019.2008.00226.x-BIB84","first-page":"S77","article-title":"Global safety and efficacy of up to five years of etanercept (Enbrel\u00ae) therapy","volume":"44","author":"Klareskog","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB85","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1586\/17469872.2.6.707","article-title":"Update on infliximab: an intravenous biologic therapy for psoriasis","volume":"2","author":"Pearce","year":"2007","journal-title":"Expert Rev Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB86","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.berh.2006.06.002","article-title":"Problems encountered during anti-tumour necrosis factor therapy","volume":"20","author":"Desai","year":"2006","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB87","unstructured":"87. Conway PA , Reeves P , Lloyd A , Baxter G. Cost effectiveness in patients with plaque psoriasis meeting BAD criteria for biological interventions. Br J Dermatol 2006: 155(Suppl. 1): 33-34."},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB88","first-page":"1","article-title":"Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation","volume":"10","author":"Woolacott","year":"2006","journal-title":"Health Technol Assess"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB89","unstructured":"89.National Institute for Health and Clinical Excellence. Etanercept and infliximab for the treatment of adults with psoriatic arthritis. London (UK): National Institute for Health and Clinical Excellence (NICE); July 2006, 33 pp. (Technology Appraisal Guidance; no. 104)."},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB90","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/rheumatology\/kem221","article-title":"The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis","volume":"46","author":"Bravo Vergel","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB91","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/rheumatology\/kel147","article-title":"Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis","volume":"45","author":"Bansback","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB92","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2165\/00002512-200724030-00005","article-title":"Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis","volume":"24","author":"Fleischmann","year":"2007","journal-title":"Drugs Aging"},{"key":"10.1111\/j.1529-8019.2008.00226.x-BIB93","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2133.2005.06893.x","article-title":"British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005","volume":"153","author":"Smith","year":"2005","journal-title":"Br J Dermatol"}],"container-title":["Dermatologic Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1529-8019.2008.00226.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1529-8019.2008.00226.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T10:11:10Z","timestamp":1738404670000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1529-8019.2008.00226.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":93,"URL":"https:\/\/doi.org\/10.1111\/j.1529-8019.2008.00226.x","relation":{},"ISSN":["1396-0296","1529-8019"],"issn-type":[{"type":"print","value":"1396-0296"},{"type":"electronic","value":"1529-8019"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}